type 2 diabetes
Conditions
Interventions
Hengagliflozin Group:Based on current clinical practice, researchers prescribe Hengagliflozin 5mg or 10mg QD
Sponsors
Central People's Hospital of Zhanjiang
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) The patient was diagnosed as type 2 diabetes according to the Chinese Guidelines for the Prevention and Treatment of Type 2 diabetes (2020); (2) Age = 18 years old, regardless of gender; (3) Glycated hemoglobin (HbA1c) = 11% or fasting blood glucose = 13.3mmol/L; (4) Be able to understand the content and methods of this study and voluntarily sign an informed consent form; (5) Not previously using sodium glucose cotransporter 2 inhibitors (SGLT2 inhibitors) or discontinuing medication for more than 7 days after use; If non SGLT2i hypoglycemic drugs are used, a stable dose should be maintained for at least 4 weeks; (6) Glomerular filtration rate (eGFR) = 30mL/min/1.73?.
Exclusion criteria
Exclusion criteria: 1) Diabetes ketosis or ketoacidosis, diabetes hypertonic state, diabetes lactic acidosis and other acute diabetes complications or serious chronic diabetes complications; 2) Use uric acid lowering drugs, diuretics, or high-dose aspirin; 3) History of gouty arthritis attacks in the past 8 weeks; 4) Individuals with clinically significant urinary tract infections and/or genital infections, or a history of recurrent urinary tract infections and/or genital infections; 5) Serious lesions in important organs such as the heart, liver, kidneys, and brain; 6) Patients with malignant tumors, active tuberculosis, and acute or chronic infections; 7) Individuals with mental or neurological disorders who are unwilling to communicate or unable to fully understand and collaborate; 8) Pregnant or lactating women, as well as women of childbearing age who are unwilling to take reliable contraceptive measures; 9) Individuals known to be allergic to Hengge Lie Jing; 10) Currently participating in or having participated in any other clinical trials within the past 3 months; 11) In addition to the above, the researchers have determined that patients who are not suitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum uric acid; | — |
Secondary
| Measure | Time frame |
|---|---|
| Urinary albumin/creatinine ratio;glomerular filtration rate;glycosylated hemoglobin; | — |
Countries
China
Contacts
Public ContactChun Huang
Central People's Hospital of Zhanjiang
Outcome results
None listed